Yangzhou Wang PhD’s Post

Orna Therapeutics is pursuing in vivo delivery of CARs, which would eliminate the need for lymphodepletion and address the reliance of proximity to large cancer centers and the rising costs of cell therapies. Dr Robert Mabry, Orna’s CSO, shares how Orna is using circular RNA for the next generation of CARs. Read the interview here: https://lnkd.in/eRR8V_qy

Through her research, Mara Goldstein explains how she is helping bring capital to companies to develop novel products and technologies for treating cancer. Read the interview with Mara below! https://lnkd.in/eCiGDVve

Guten Tag, Berlin! 🔥 I have just arrived here for a few days; please message me to discuss the intersection of AI and Bio, techbio, and the future of drug discovery & cancer treatment! 🚀 Let's make some memorable connections. #berlin #techbio #immunotherapies #deepflare #ai

Recently, I had the pleasure of sitting down with Ajit Singh, a healthcare luminary and change agent. Our conversation covered a variety of topics including the future of AI in pharma, oncology, diagnostics, neurotechnology, and more. As someone who is fortunate enough to meet and interview some of the smartest people in the world, I can confidently say that this conversation is not to be missed. Check it out here: https://lnkd.in/gFw69vuA #healthcare #AI #pharma #oncology #diagnostics #neurotechnology

Learn how to customize your humanized mice models for preclinical cancer research based on specific research questions and data requirements in this live webinar on April 16, 2024, 1:00 PM ET https://lnkd.in/gu4_iGbJ #humanized #mice #model #research

Patient-Derived Xenografts (PDX) are the gold standard in oncology drug development models. In this webinar Julia Schueler will give you insights on how in silico, in vitro, and in vivo PDX tools can optimize your preclinical phase, thanks to translationally relevant tumor biology models. #drugdiscovery #pdx #oncology #3Dmodels

🎄Happy New Year to all my friends🥂 💚💚Wishing you all the best full of satisfaction and happiness 💚💚 I am delighted to share that our recent article entitled "Targeted co-delivery of FOXM1 aptamer and DOX by nucleolin aptamer-functionalized pH-responsive biocompatible nanodelivery system to enhance therapeutic efficacy against breast cancer: in vitro and in vivo" has been published at esteemed Journal, Drug Delivery and Translational Research. What could be more motivating to pursue in 2024!🥂👍

It was insightful to listen to what investors are after in regard to biopharmacology. As Advalyst, continues to boost its idea-stage biopharma start-up (advanced cancer inhibitors) founding team, scanning the worldwide VC investment landscape, is educating. #bioengineering #computationalpharmacology #ai #clinicaltrialsimulators #opensourceAI

Comprehensive landscape of Cell Therapy

Good overview to help navigate cell types in the Cell Therapy Oncology landscape.